Association Between Ferroquine and an Artemisinine Derivative for Treating Malaria
This invention is directed to methods for the treatment and prevention of malaria comprising administering a combination of ferroquine, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and an artemisinin derivative, and to pharmaceutical compositions comprising such combination.
1 . A method for the treatment of malaria in a patient in need thereof, comprising administering to such patient a therapeutically effective amount of a combination of ferroquine, in the form of a free base or a pharmaceutically acceptable salt thereof, and an artemisinin derivative.
2 . A method according to claim 1 , wherein the artemisinin derivative is selected from group consisting of artesunate, arteether and artemether.
3 . A method according to claim 2 , wherein the artemisinin derivative is selected from the group consisting of artesunate and artemether.
4 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, is administered in a dose of between 50 mg and 1600 mg per person per day.
5 . A method according to claim 4 wherein the dose administered is between 200 mg and 1200 mg per person per day.
6 . A method according to claim 5 wherein the dose administered is between 400 mg and 800 mg per person per day.
7 . A method according to claim 1 wherein the artemisinin derivative is administered in a dose of between 1 mg/kg and 10 mg/kg per day.
8 . A method according to claim 7 wherein the dose administered is between 2 mg/kg and 6 mg/kg per day.
9 . A method according to claim 8 wherein the dose administered is about 4 mg/kg per day.
10 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, is administered in a dose of between 50 mg and 1600 mg per person per day, and wherein the artemisinin derivative is administered in a dose of between 1 mg/kg and 10 mg/kg per day.
11 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, and the artemisinin derivative are administered over a period of 2, 3 or 4 consecutive days.
12 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, and the artemisinin derivative are administered simultaneously.
13 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, and the artemisinin derivative are administered sequentially.
14 . A pharmaceutical composition comprising a therapeutically effective dose of ferroquine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one artemisinin derivative, and at least one pharmaceutically acceptable excipient.
15 . A pharmaceutical composition comprising a therapeutically effective dose of a combination of ferroquine, or a pharmaceutically acceptable salt thereof, and at least one artemisinin derivative, and at least one pharmaceutically acceptable excipient.
16 . A pharmaceutical composition according to claim 14 wherein the artemisinin derivative is selected from the list consisting of artesunate, arteether and artemether.
17 . A pharmaceutical composition according to claim 16 wherein the artemisinin derivative is selected from the list consisting of artesunate and artemether.
18 . A pharmaceutical composition according to claim 15 wherein the artemisinin derivative is selected from the list consisting of artesunate, arteether and artemether.
19 . A pharmaceutical composition according to claim 18 wherein the artemisinin derivative is selected from the list consisting of artesunate and artemether.
20 . A method according to claim 1 wherein the ferroquine, or pharmaceutically acceptable salt thereof, is administered orally, rectally or by infection, and the artemisinin derivative is administered orally, rectally or by injection.
21 . A kit for the treatment or of malaria, comprising, firstly, ferroquine or a pharmaceutically acceptable salt thereof and, secondly, at least one artemisinin derivative, said ferroquine and said artemisinin derivative being in distinct compartments and being intended to be administered simultaneously or sequentially.